FULC Live signaler | Maksimer profitt med Getagraph.com

SELG 115926 min ago

@ $8.91

Utstedt: 14 feb 2024 @ 20:26

Avkastning: -13.02%

Forrige signal: feb 13 - 21:22

Forrige signal: Kjøp

Avkastning: -1.22 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	198 560
Gjennomsnittsvolum	625 969
Markedsverdi	480.00M
EPS	$0 ( 2024-02-27 )
Neste inntjeningsdato	( $-0.440 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.87
ATR14	$0.0120 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Horn Patrick Taylor	Buy	400 000	Stock Option (right to buy)
2024-03-18	Horn Patrick Taylor	Sell	0	No securities are beneficially owned
2024-03-08	Tourangeau Greg	Sell	4 884	Common Stock
2024-03-04	Sapir Alex	Buy	43 360	Common Stock
2024-01-26	Tourangeau Greg	Buy	83 820	Stock Option (right to buy)

INSIDER POWER
20.72
Last 98 transactions
Buy: 8 691 029 \| Sell: 9 119 346

Volum Korrelasjon

Lang: -0.21 (neutral)

Kort: -0.69 (moderate negative)

Signal:(42.469) Neutral

Fulcrum Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
ABST	0.942
CSX	0.939
MULN	0.929
VNET	0.928
ALLO	0.927
RLMD	0.92
CNDT	0.919
IDLB	0.918
PTH	0.917
EGAN	0.917

10 Mest negative korrelasjoner
RMRM	-0.949
RDUS	-0.927
XOG	-0.9
TYHT	-0.895
EPZM	-0.881
RTPY	-0.876
SVOK	-0.874
OPCH	-0.871
SYKE	-0.868
HSTM	-0.864

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Fulcrum Therapeutics Inc Korrelasjon - Valuta/Råvare

0.35
( neutral )

0.37
( neutral )

-0.46
( neutral )

0.25
( neutral )

0.01
( neutral )

Fulcrum Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$2.81M
Bruttogevinst:	$633 000 (22.57 %)
EPS:	$-1.590

FY	2023
Omsetning:	$2.81M
Bruttogevinst:	$633 000 (22.57 %)
EPS:	$-1.590

FY	2022
Omsetning:	$6.34M
Bruttogevinst:	$3.93M (61.94 %)
EPS:	$-2.35

FY	2021
Omsetning:	$19.16M
Bruttogevinst:	$19.16M (100.00 %)
EPS:	$-2.29

Financial Reports:

No articles found.

Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.